Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vistin Pharma ASA: Invitation to Q2 2026 conference call

VISTNRegulatory press release2026-08-13 10:30
Oslo, Norway, 13 August 2026

Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results
on Thursday 20th of August 2026. Vistin Pharma will host a conference call for
all shareholders and other interested parties on the same day at 08:30 CET.
There will be a Q&A session following the management discussion.

The second quarter conference call will be accessible via web and audio through
the following access points:

Webcast: https://edge.media-server.com/mmc/p/abe93pzc

Telephone conference (online registration):

https://register-conf.media-
server.com/register/BIca3298faa94f4bbb900f07289bc40eb7 (https://register-
conf.media-server.com/register/BI83c6eca2da3d47c3bec047d0633a0501)

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.
icated manufacturing facility in Kragerø.\